COAG — Hemab Therapeutics Holdings Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Hemab Therapeutics Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2024 December 31st | 2025 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG |
| Status: | Final | Final |
| Net Income/Starting Line | -48.7 | -63.9 |
| Depreciation | ||
| Non-Cash Items | 1.42 | 0.779 |
| Other Non-Cash Items | ||
| Changes in Working Capital | 1.45 | 1.35 |
| Change in Prepaid Expenses | ||
| Change in Other Assets | ||
| Change in Accounts Payable | ||
| Change in Accrued Expenses | ||
| Change in Other Liabilities | ||
| Cash from Operating Activities | -45.6 | -61.5 |
| Capital Expenditures | -0.282 | -0.016 |
| Purchase of Fixed Assets | ||
| Other Investing Cash Flow Items | 62.2 | -81.5 |
| Sale/Maturity of Investment | ||
| Purchase of Investments | ||
| Cash from Investing Activities | 61.9 | -81.5 |
| Net Issuance / Retirement of Stock | ||
| Net Issuance / Retirement of Debt | ||
| Cash from Financing Activities | -0.1 | 156 |
| Foreign Exchange Effects | ||
| Beginning Cash Balance | ||
| Ending Cash Balance | ||
| Net Change in Cash | 16.2 | 13.6 |